Talaris Therapeutics, Inc.

As of June 9, 2025, Talaris Therapeutics, Inc. shows a mildly bearish trend due to daily moving averages, despite some bullish signals from weekly indicators, while monthly metrics indicate bearish tendencies.

Talaris Therapeutics, Inc. is a micro-cap company in the Pharmaceuticals & Biotechnology industry, currently reporting a net profit loss of $23 million and a market cap of $466.18 million. Key financial metrics include a negative P/E ratio, a debt equity ratio of -0.89, and a return on equity of -29.61%.

As of Jun 18, Talaris Therapeutics, Inc. has a market capitalization of 466.18 million, with net sales of 0.00 million and a net profit of -82.87 million over the latest four quarters. The company reported shareholder's funds of 300.05 million and total assets of 309.00 million as of Dec 24.